BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $12.00 price objective on the biotechnology company’s stock.

BioCryst Pharmaceuticals Stock Up 1.5 %

Shares of BCRX stock opened at $4.87 on Wednesday. The stock has a market cap of $1.00 billion, a P/E ratio of -4.13 and a beta of 1.90. The business has a fifty day simple moving average of $5.30 and a 200-day simple moving average of $5.72. BioCryst Pharmaceuticals has a fifty-two week low of $4.45 and a fifty-two week high of $9.06.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $89.19 million. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.62 earnings per share for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Braidwell LP lifted its stake in shares of BioCryst Pharmaceuticals by 92.1% in the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock valued at $37,970,000 after purchasing an additional 2,571,100 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 15,392,319 shares of the biotechnology company’s stock valued at $108,978,000 after purchasing an additional 302,270 shares in the last quarter. Jump Financial LLC lifted its stake in shares of BioCryst Pharmaceuticals by 371.5% in the 3rd quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company’s stock valued at $2,867,000 after purchasing an additional 319,037 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of BioCryst Pharmaceuticals by 148.6% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock valued at $23,265,000 after purchasing an additional 1,964,000 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company’s stock valued at $16,112,000 after purchasing an additional 402,674 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.